Back to Top

Information For Authors

AIMS & SCOPES
Androgens: Clinical Research and Therapeutics is the premier global journal for peer-reviewed science, research, and education regarding the effects of the presence, deficiency, and use of testosterone and other androgens in diverse patient populations and the influence of these hormones on multiple disease states and conditions. The journal brings all disciplines of medicine and healthcare into one centralized platform covering the numerous areas of study, including urology, sexual and reproductive medicine, endocrinology, aging, fertility, psychiatry and behavioral sciences, oncology, cardiology, dermatology, ophthalmology, and more.  The journal publishes on a continuous cycle on an Open Access platform.

ARTICLE PUBLICATION CHARGES (APCs)
Androgens: Clinical Research and Therapeutics is a fully Open Access journal. Article Processing Charges (APCs) are being waived by the Publisher through August 31, 2021.

All articles published in Androgens: Clinical Research and Therapeutics are made freely and permanently accessible on the Publisher’s website upon publication without access or subscription charges, embargo periods, or user registration.

CLICK HERE for more information about OPEN ACCESS / CC-BY LICENSING INFORMATION

See JOURNAL STANDARDS AND BEST PRACTICES STATEMENT  

Check the Journal’s PEER REVIEW POLICIES

MANUSCRIPT PREPARATION
Please read all instructions below before submitting your paper.  Click here to begin your submission.

DETERMINING AUTHORSHIP
See AUTHORSHIP DEFINITION AND RESPONSIBILITIES
All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results.

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

CLICK HERE FOR ARTICLE TYPES AND WORD LIMITS

SUBMISSION PROCESS
All Original submissions must contain:

  • An Internal Review Board (IRB) approval (or waiver) statement in the Methods section
  • An Author Contribution statement for each author, followed by
  • An Author Disclosure Statement for each author listed on a submission after the Acknowledgments section, followed by,
  • Funding statement(s), even if there is no funding information to declare.

See IRB APPROVALS, PATIENT CONSENT, & ETHICAL TREATMENT OF ANIMALS

See AUTHOR CONFIRMATION AND DISCLOSURE STATEMENTS

See FUNDING INFORMATION: COMPLIANCE AND STATEMENTS


All manuscripts must be prepared in accordance with the Uniform Requirements for Manuscripts Submitted for Biomedical Journals.

When ready to submit your manuscript for peer review, be prepared to :

  • Enter the full title of the manuscript
  • Enter the full names and institutional affiliations of ALL listed authors
  • Enter ALL listed authors' institutional email addresses
  • Identify the corresponding author
  • Enter a running (abbreviated) title of no more than 50 characters (including spaces).
  • Enter 3–5 keywords or phrases.
  • Provide a structured abstract of no more than 250 words, stating the background, methods, and results (including the sample size), drawn from the study.
  • Provide the names and email addresses of at least five potential preferred reviewers familiar with the field.  Please make sure preferred reviewers are not from your university or institution or with whom you have collaborated.  Anyone whom the author does not want to be considered should also be named as a non-preferred reviewer.   Ultimate reviewer selection is at the Editor’s discretion.
  • Confirm that the material has not been published or submitted for publication elsewhere.

FILE NAMING
When naming your figure files, please label them in English with the corresponding author’s last name, followed by the figure number, wthout spaces.  Use only alphanumeric characters; do not use symbols or underscores (Ex:  JonesFig1).  

Important:  Please upload individual files of all manuscript material as described herein — please do NOT upload a combined PDF file containing all material in your submission.  

PREPARATION OF MANUSCRIPT

  • Prepare text of manuscripts in Microsoft Word, double spaced. The order of elements in each manuscript should be:
  • Title page (with full manuscript title, all contributing authors and their affiliations, a short running title, a denotation of the corresponding author, and a list of 3-6 keywords
  • Abstract
  • Main text (do not embed figures or tables)
  • Conclusion (as a separate paragraph, not as part of the Discussion section)
  • Acknowledgments (if applicable)
  • Authorship confirmation statement (see below)
  • Author(s’) disclosure statement(s) (see below)
  • Funding statement (see below)
  • References
  • Figure legends
  • Tables
  • Supplemental Information (if applicable); NOTE: Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)

Text. 
Maximum word count should not exceed 4,000 words.  In general, the text should be organized under the headings: Introduction, Materials and Methods, Results, Discussion, and Conclusions. Use only standard abbreviations, which can be found in the AMA’s Manual for Authors & Editors or the Council of Biology Editors Style Manual, 10/e.  At first usage, spell out terms and give abbreviations in parentheses. Thereafter, use only abbreviations. It is not necessary to spell out standard units of measure. Use generic names for drugs if possible. If you wish to use a proprietary drug name the first time it appears, use the generic name followed by the proprietary name, manufacturer, and location in parentheses.

Acknowledgments
The author should acknowledge only those people and their institutions that have made significant contributions to the study.  This text should be listed after the conclusion section.

References  
References must be prepared double spaced and numbered consecutively as they are cited in the text (using superscript numbers), and should part of the main text file, not prepared separately. References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned. Use journal abbreviations as provided by PubMed/Medline. List all authors when there are six or less. When there are more than six, list the first three, followed by et al. If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (AB Jones, personal communication). Include among the references any papers that have been accepted but have not yet published; identify the name of publication and add "In Press." If the reference has been published online, provide the DOI number in place of the page range.  

Style sample for references:

  • Journal paper with up to six authors:  

Bienenfeld A, Azarchi S  , Lo Sicco K, Marchbein S, Shapiro J,  Nagler AR. Androgens in women: Androgen-mediated skin disease and patient evaluation.  J Am Acad Dermatol. 2019;80(6):1497–1506.

  • Journal paper with more than six authors:  

Wang PH, Chen YL, Wei ST, et al. Retroconversion of estrogens into androgens by bacteria via a cobalamin-mediated methylation.  Proc Natl Acad Sci USA. 2020;117(3):1395–1403.

  •  Book:

Hellstrom WJG. Androgen Deficiency and Testosterone Replacement: Current Controversies and Strategies.  Totawa, NJ: Humana Press (Springer) 2012.

  • Chapter in a book:  

Kramer AC.  Effects of androgen deficiency and replacement on male fertility.  In:  Androgen Deficiency and Testosterone Replacement: Current Controversies and Strategies (Hellstrom WJH, ed).  Totawa, NJ: Humana Press (Springer). 2012; pp 95–102.

Legends
Figure legends should be uploaded as a separate Word file and double spaced. In the legend, provide explanations for any abbreviations, arrows, etc. that appear in the figure. If the illustration is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.  
 
Tables
All tables should be prepared in one single Word file. Provide a title for each table. Cite tables in sequence in the text. Explain abbreviations used in the body of the table in footnotes. If the table is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.   

Figures
Cite figures consecutively in the manuscript within parentheses.  A legend should be supplied for each figure and all legends numbered consecutively.  Images should not show the name of a patient or a manufacturer.  

  • Do not include any illustrations as part of your text file.
  • Do not prepare any figures in Word as they are not workable.
  • Line illustrations must be submitted at 900 DPI.
  • Halftones and color photos should be submitted at a minimum of 300 DPI.
  • Save art as either TIFF or EPS files.  Avoid submitting JPEG files.
  • Color art must be saved as CYMK not RGB.

Correspondence Address
Following the references, provide the name and complete address of the person to whom correspondence should be sent.

LETTERS TO THE EDITOR
Androgens: Clinical Research and Therapeutics will consider Letters to the Editor commenting on the scientific content of an article published in the Journal. Letters should not exceed 400-500 words of text and 5 references. Letters submitted for publication must be original and must not be submitted to any other publication simultaneously.

Be sure to review the Journal’s policies on the following:
Data Sharing and Preprint Policies
Post-Acceptance and Post-Publication Policies
Correction Statements / Retractions
Reprints, Permissions, & Social Media Use
Plagiarism Detection Software
Definitions of Scientific Misconduct
Responding to Allegations of Scientific Misconduct
Press Embargo Policy
Publication Costs
Archiving and Preservation
Publisher Information

 

Androgens Clinical Research and Therapeutics is a single-blinded peer reviewed journal. All submissions are subject to peer review. Upon submission, manuscripts are assessed by the Editor, Associate Editor, or member of the editorial board for suitability for Androgens: Clinical Research and Therapeutics.  For those that are deemed appropriate, a minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper requires further revision, is accepted in its current form, or is unacceptable for publication.

Confidentiality in Peer Review
Editors and reviewers must maintain strict confidentiality of manuscripts during the peer review process.  Sharing a manuscript in whole or in part is impermissible prior to its official publication date.

Reviewers are expected to retain their anonymity and are prohibited from contacting authors directly.  All content of any submission is considered private and confidential and should not be shared with anyone without the express written approval of the Editor(s)-in-Chief of Androgens: Clinical Research and Therapeutics.

Sharing of Materials during Peer Review
Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.

Peer Review of Papers Authored by the Editor(s)-in-Chief and/or Associate Editor(s)
The Editor(s)-in-Chief and Associate Editor(s) will recuse themselves from participating in the review process of any manuscript in which they are listed as an author and/or if there is a potential or actual competing interest.  The peer review process on these submissions will be handled by another senior member of the editorial board.

Self-Citation and Self-Plagiarism
Androgens: Clinical Research and Therapeutics is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles.  Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.  (Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any submitted manuscript.)

Time in Review
The journal strives to maintain a short, but thorough peer review process. The average time in review is 21 days but the Editor will strive to expedite manuscript handling if circumstances dictate.

Androgens: Clinical Research and Therapeutics is a fully Open Access journal. Article Processing Charges (APCs) are being waived by the Publisher until August 15, 2020.

Open Access and Copyright

All articles published in Androgens: Clinical Research and Therapeutics are made freely and permanently accessible on the Publisher’s website upon publication without access or subscription charges, embargo periods, or user registration.

Once a manuscript is accepted for publication, the author(s) will sign an Open Access Licensing Agreement. Authors of articles published in the Journal will be the copyright holders and a Creative Commons CC BY license will be applied. For more information, please read the full Creative Commons CC BY license.

For authors who are U.S. government employees or who are prevented from being copyright holders, Liebert Open Access can accommodate non-standard copyright. For more information, please CLICK HERE to contact our Open Access Manager.

ATTENTION: 
To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

•    manuscriptcentral.com
•    amazonses.com
•    liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

AUTHORSHIP

Definition of Authorship
Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria:

•    Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
•    Drafting the work or revising it critically for important intellectual content; AND
•    Final approval of the version to be published; AND
•    Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Non-Author Contributors
Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.
For further information, visit the International Committee of Medical Journal Editors’ website.

ORCID IDs
All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

AUTHORSHIP LIMIT
There is a limit of 35 of authors permitted on a single submission, but in cases where there are 20 or more co-authors, Androgens: Clinical Research and Therapeutics recommends that a collective working group, team, or consortium name be provided and the individual authors and their affiliations listed in the Acknowledgements section.  This will ensure the proper listing of all authors in the indexing services in which Androgens: Clinical Research and Therapeutics is included.

CORRESPONDING AUTHOR**
One author should be designated on the manuscript title pages as the corresponding author who will be responsible for communication between the authors and the journal editorial office(s) and publisher.  This individual will be responsible for ensuring all authors submit copyright forms as well as receiving and responding to page proofs, and managing any other necessary contact during the peer review and/or production processes.
**NOTE: Due to configuration restraints, the submission system permits only one author to be identified as the corresponding author of record.  However, we recognize that some submissions call for more than one corresponding author to be noted.  In such cases, select one author to be the main point of contact and/or corresponding author for all communications regarding the peer review process of the paper, but on the title page of the manuscript, designate additional co-corresponding authors by including an asterisk after the authors' names in the byline, and include an accompanying footnote on the title page that reads, "Co-corresponding authors."  Please ensure that the title page of the submission page carries the full affiliation details and email addresses of all authors who should be noted as a corresponding author. If the paper is accepted for publication, the full contact information for all designated co-authors will be listed at the end of the article as per usual journal style.

WORKING GROUPS / TEAMS/ CONSORTIUMS AUTHORSHIP
Working Groups, teams, or consortiums may be listed as an “author” in the manuscript byline, but the complete listing of members’ names and affiliations should be included in the Acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.

VARIATIONS OF AUTHORSHIP
It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include an asterisk (*) next to the authors' names who are considered as first authors, and a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."

CHANGES IN AUTHORSHIP  
Authorship should be determined prior to submission.  Submitting agents should use extreme care to ensure the accuracy of the author list and their correct affiliations.  Changes in authorship after submission or acceptance of a paper are generally not permitted, but the editorial leadership recognizes that it may be required in certain extraordinary and rare circumstances. The policy of Androgens: Clinical Research and Therapeutics for such cases is as follows:

•    Authorship may be altered after submission or acceptance of a paper ONLY with the express written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher will provide a specialized form that all authors will be required to sign and return.
•    A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
•    Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
•    Authorship will not be altered without the completed and signed forms from each author.
•    Alterations of authorship post-publication is not permitted.
•    Post-publication changes or alterations to authorship of published conference abstracts are not permitted.

ATTENTION: 
To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

•    manuscriptcentral.com
•    amazonses.com
•    liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

EXCLUSIVITY  
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference/meeting abstract.  If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission.

USE OF ENGLISH LANGUAGE  
All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Androgens: Clinical Research and Therapeutics. For authors whose native language is not English, we recommend using a service that will aid in the translation and rewriting of material into correct and proper English usage. The Publisher offers this service for a fee prior to official submission. For more information, please contact: Editing@liebertpub.com Please note that employing the use of the Publisher's service is not required and using it, or any other language editing service, does not guarantee acceptance of any paper. All submissions are subject to peer review.

AUTHOR DISCLOSURE STATEMENTS
•    Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
•    Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
•    Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
•    Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
•    Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

FUNDING INFORMATION
Manuscripts should be submitted with all appropriate funding agency information, including all grant numbers, in order for proper appropriation and deposition to official databases (i.e., PubMed Central [PMC]), and indexing services.

If an article is published without this information and a post-publication correction is requested, authors will be required to provide original documentation from the funding agency specific to the study in order for an official correction statement to be considered by the Editor of Androgens: Clinical Research and Therapeutics.

SELF-CITATION AND SELF-PLAGIARISM  
Androgens: Clinical Research and Therapeutics is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. Any manuscript to be considered for publication will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

AFFILIATIONS
Authors should identify as their institution(s) the facility where the work was performed and executed.  Changes in an author’s affiliation after the work was completed but prior to the submission or publication of the manuscript should be noted by including an asterisk as a superscript to the name in the author listing, as well as a corresponding footnote on the title page indicating “Current Address” listing the new affiliation.   Corrections to affiliations, email addresses, or contact information due to relocation after publication is not permitted.

 

Word limits do NOT pertain to the abstract, disclosure statements, author contribution statements, funding information, acknowledgments, tables, figure legends, or references.

Original Articles
•    3,000-word limit
•    Structured abstract of no more than 250 words
•    Maximum of eight (8) tables and/or figures

Reviews
•    A range between 4,000-6,000-word it
•    Unstructured abstract of no more than 300 words
•    Maximum of ten (10) tables and/or figures

Mini Reviews
•    2,500-3,000-word limit
•    Unstructured abstract of no more than 250 words
•    Maximum of five (5) tables and/or figures

Brief Reports
The results of preliminary studies, pilot programs, or small series on which an hypothesis can be formulated and tested in a subsequent study are good candidates for this category.
•    1,500-word limit
•    Structured abstract of no more than 150 words

Perspectives
This type of submission should present a new or unique viewpoint on existing problems or fundamental concepts on a specific topic and should introduce and/or suggest a new hypothesis. Perspective pieces may include original data as well as personal opinion. Alll submitted Perspectives are subject to peer review.

•    2000-3000 word limit
•    Unstructured abstract of no more than 150 words
•    Maximum of four (4) tables and/or figures.
•    Maximum of ten (10) references

Commentaries
A Commentary may be invited by the Editor(s), or unsolicited.  These submissions should address a critical issue and/or need in the field

•    1,000-1,500 word limit
•    Abstract not required
•    Maximum of two (2) tables and/or figures
•    Maximum of five-ten (5-10) references

Authors of any unsolicited commentary are required to submit a proposal to the editor who will decide whether or not to encourage submission. An affirmative response from the editor does not influence the subsequent peer-review process or editorial decision (re: accept or reject).

Letters to the Editor
Results of research or the development of ideas that do not fit the criteria for a Brief Report may be reported in a Letter. Letters are intended to transmit information that is much more “raw” or “untested,” but holds promise in furthering the field through stimulating further research, discussion, or resolving controversy.

•    500-word limit
•    May include one figure OR table
•    Reference citations are identical in style to those of full original articles, but should not exceed five (5).

 

For further information, consult the World Medical Association’s website

INTERNAL REVIEW BOARD APPROVALS/WAIVERS
(as described and defined on the World Medical Association's website)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

If the study is judged exempt from review, a statement from the committee is be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included at the beginning of the Materials and Methods section of the manuscript.

Human Subjects:  Patient Consent/Release
If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images and/or information of patients.

Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.  Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.

In keeping with patients' rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests they have received and archived written patient consent.  A statement of patient consent must be included in the Methods section of the manuscript.

Ethical Treatment of Animals
All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

 

Author Contribution Statement(s)

Authors are required to include a statement of responsibility in the manuscript after the Acknowledgments section that specifies the contribution of each author listed on the submission. If a paper is accepted for publication, these statements are published as part of the article.  Click here for the definition of Authorship.

Author Disclosure Statements

•    Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
•    Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
•    Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
•    Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
•    Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

RESEARCH FUNDER COMPLIANCE (FundRef)
Upon submission of a manuscript, the submitting agent will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata to FundRef. The entered information should include funder names, funder IDs (if available), and associated grant numbers.  Special care should be taken when entering this information to ensure total accuracy. (See CrossRef's Funder Registry for a listing of more than 13,000 international funding agencies.)

GOVERNMENT FUNDED RESEARCH
Androgens is fully NIH-, HHMI-, RCUK, and Wellcome Trust-compliant.

OPEN ACCESS
Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), Howard Hughes Medical Institute (HHMI) the Wellcome Trust, or Research Councils UK (RCUK), please note below:
•    NIH and HHMI Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
•    Wellcome Trust Policy: To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
•    Research Councils UK (RCUK):  To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RCUK.

FUNDING INFORMATION
Manuscripts must contain a formal Funding Information Statement which includes all appropriate funding agency information and grant numbers, in order for proper appropriation and deposition to official databases (i.e., PubMed Central [PMC]), and indexing services.  A statement should be inlcuded even if no funding was received.

If an article is published without this information and a post-publication correction is requested, authors will be required to provide original documentation from the funding agency specific to the study in order for an official correction statement to be considered by the Editor of Androgens.

DATA SHARING

Androgens strongly advocates the sharing and archiving of the data and any other artifacts that define and support the results stated in a manuscript in a suitable public repository (in accordance with valid privacy, legal, and ethical guidelines). A data availability statement should be included in the manuscript (in the Methods section or as a separate section at the end of the manuscript), describing the location of the data, with details on how it can be accessed as well as any licensing information. If the data is not publicly available or accessible, that information should also be provided.

Datasets should be cited in the reference list by Author (Year). Title. Publisher. Identifier/DOI.

Important: Please check with your funding agencies to ensure that are you following their data sharing polices. If your funding agency has additional requirements exceeding our policy, you must follow the requirements of your funder.

PREPRINT SERVERS

A preprint is a complete draft of a research paper that is shared on a public preprint server prior to submission to a journal for peer review.
 
Mary Ann Liebert, Inc., allows for papers that were previously deposited on preprint servers to be submitted to our journals, with the proviso that the author updates any preprint versions with a link to the final published article.  All submissions are subject to peer review and allowing the submission of preprint manuscripts does not guarantee publication in any Mary Ann Liebert, Inc., journal.
 
The submitting author of a paper that was previously deposited to a preprint server should include a disclosure on the title page of the manuscript indicating the name and website of the server and include the DOI number of the preprint.
 
Referencing/citing non-peer-reviewed material that is found on any preprint server is generally discouraged by Mary Ann Liebert, Inc., journals, but if it is necessary, the citation must make it clear that the content is not officially published in a journal, and can only be found on a preprint server.

 

ATTENTION:  
To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

•    manuscriptcentral.com
•    amazonses.com
•    liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

POST-ACCEPTANCE / PRODUCTION
All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Depending on the length and complexity of any accepted submission, these steps typically take 3-6 weeks from acceptance.  Changes or alterations to a submission are not permitted after acceptance but should be addressed in page proofs.

PAGE PROOFS
Page proofs will be sent to the corresponding author as designated in Manuscript Central when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors, if desired, and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors/sources.

AUTHOR RESPONSE TO GALLEY PROOF
•    The corresponding author is responsible for returning corrected galley proofs generally within 72 hours of receipt.
•    If the corresponding author does not respond within that timeframe, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher.
•    If the corresponding author expects to be unavailable during the time the manuscript is in production, the Publisher should be provided with an alternate contact.  
•    Only corrections directly related to errors in typesetting and/or layout will be allowed.
•    Any requested changes related to content, or that alter the outcome of a study, will require the approval of the Editor, and may require further peer review.

POST-PUBLICATION CORRECTIONS
In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration.  After editor approval, alterations will be made to the online version of the article, and if the errors are significant, an official correction statement will be issued.

•    Changes to author affiliations or contact details due to relocation after publication are not permitted.
•    Corrections to meeting abstracts will be made only to the online version.  The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.
•    Correction Statements/Errata to published articles due to author error that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).

CORRECTIONS TO FUNDING INFORMATION
Manuscripts should be submitted with all appropriate funding agency information, including all grant numbers, in order for proper appropriation and deposition to official databases (i.e., PubMed Central [PMC]), and indexing services.

If an article is published without this information and a post-publication correction is requested, authors will be required to provide original documentation from the funding agency specific to the study in order for an official correction statement to be considered by the Editor of Androgens: Clinical Research and Therapeutics.

PRESS EMBARGOS
Mary Ann Liebert, Inc., publishers permits the use of accepted pre-published manuscripts for the sole purpose of pitching to news organizations under strict embargo, and with the approval of and expressed collaboration with the publisher. A watermarked PDF version of the article (not a Word document or any other editable version) may be shared only with named, personal contacts at trusted news sources upon request. News sources must be informed upon delivery of the PDF that the manuscript is for reference-only purposes and can be used only in preparation of their news coverage of the article. It is strictly prohibited to publicly share, post, or otherwise distribute the PDF in any media format. Upon official publication of the article, news organizations must link directly to the published article on the publisher’s journal website. To coordinate publication timing and press efforts, please CLICK HERE contact our Director of Marketing.

RETRACTIONS**
Androgens: Clinical Research and Therapeutics and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted in our policies, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice will be published, explaining in full detail the circumstances surrounding the need for a retraction.
**Any publication fees for retracted and/or withdrawn articles are nonrefundable in any circumstance.

REPRINTS
Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

Policy Statement:
Retraction Notices / Expressions of Concern

The Publisher is committed to protecting the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct appropriate investigations into any reported allegations. As such, all allegations of misconduct will be referred to the Editor-in-Chief of the Journal who in turn will review the circumstances, possibly in consultation with Executive Editors, Senior Editors, Associate Editors, and/or other members of the editorial board as needed.  Initial investigations and fact-finding will include a request to all involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-in-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an Editor, an outside expert. The Editor-In-Chief and/or the Publisher may consult with our Ethics Editor(s) and will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations arise, the peer review and publication process of the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the paper is withdrawn by the authors or Editor(s). In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.  If the paper is still under peer review, the Editor-in-Chief reserves the right to withdraw the paper from consideration to the Journal.

If the accusation is with regards to a published paper, the Journal/Publisher reserves the right to publish an official “Expression of Concern” statement while the investigation is still underway.  This statement will contain the full circumstances of the complaint and will be placed directly above the published Abstract in the online version of the article.  If the investigation is not resolved by the time the next print issue of the journal is to be published, the Expression of Concern will be published as official content in the print issue.

If the investigation determines clear misconduct, the Editor-in-Chief and Publisher will officially retract the paper from the Journal and the scientific record by publishing a formal Retraction Notice both online and in print. This notice will contain all relevant details of the accusation, investigation, and the resulting conclusions.

The official Retraction Notice will replace the abstract in the online version of the article as well as in the PDF.  In addition, each page of the PDF will be watermarked with “Retracted.” The Retraction will be delivered to all associated indexing services affiliated with said journal (i.e. PubMed Central, PubMed/MEDLINE, Web of Science, etc.).

In the case where an investigation determines that no misconduct occurred, the Expression of Concern will be updated accordingly but will remain intact as part of the article and will not be removed so that readers will be notified that concerns were raised.

Editors, authors, or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal and reported to their institution.

Every attempt will be made to keep all allegations confidential.

REPRINTS
Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

PERMISSIONS
When reproducing copyrighted material such as figures, tables, or excerpted text, the author(s) of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission.  Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.

REUSE OF MATERIAL POSTED ON SOCIAL MEDIA
As material posted on social media platforms is usually not peer-reviewed content, it is generally not permitted as an official citation and/or reference.

SELF-CITATION AND SELF-PLAGIARISM
Androgens: Clinical Research and Therapeutics is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. Any manuscript to be considered for publication will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

 

DEFINITIONS OF SCIENTIFIC MISCONDUCT
Androgens: Clinical Research and Therapeutics follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

•    Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
•    Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
•    Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
•    Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
•    Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
•    Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
•    Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
•    Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
•    Simultaneous submission: Submitting a paper to more than one publication at the same time constitutes misconduct.

 

JOURNAL'S RESPONSE TO ALLEGATIONS OF SCIENTIFIC MISCONDUCT

Androgens: Clinical Research and Therapeutics and its publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of Androgens: Clinical Research and Therapeutics who, in turn, will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances, in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals. (If the allegation is against an editor, an outside expert will conduct the process.) If necessary, the Editor-in-Chief will elevate the situation to the author(s') instituional authorities and request further investigation(s), and will await the findings of the inquiry before rendering an actionable decision.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will officially retract the paper from the Journal and the scientific record, and will publish a full explanation for the necessity of the retraction. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.  Any author proved to commit scientific misconduct and/or fraud will be barred from sumbitting papers to Androgens: Clinical Research and Therapeutics.

When allegations of potential impropriety arise, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper during the process. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.  Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with  Androgens: Clinical Research and Therapeutics and reported to their institution.

All allegations of misconduct will be kept confidential.

RETRACTIONS
The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  No refunds will be issued for and fees paid in connection with an article that requires a formal post-publication withdrawal or retraction.

Mary Ann Liebert, Inc., publishers permits the use of accepted pre-published manuscripts for the sole purpose of pitching to news organizations under strict embargo, and with the approval of and expressed collaboration with the publisher. A watermarked PDF version of the article (not a Word document or any other editable version) may be shared only with named, personal contacts at trusted news sources upon request. News sources must be informed upon delivery of the PDF that the manuscript is for reference-only purposes and can be used only in preparation of their news coverage of the article. It is strictly prohibited to publicly share, post, or otherwise distribute the PDF in any media format. Upon official publication of the article, news organizations must link directly to the published article on the Publisher’s journal website. To coordinate publication timing and press efforts, please CLICK HERE to contact our Director of Marketing

•   The Publisher is currently waiving the Article Processing Charge (APC) for submissions to Androgens: Clinical Research and Therapeutics through August 31, 2021.
•    Correction Statements/Errata to published articles due to author(s') error that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).
•    No refunds will be issued for an article that requires a formal post-publication withdrawal or retraction.

 

Three versions of the article format versions are referenced in the below policy guidelines:

•    Original Submission: The article version that is submitted by the author for consideration, before peer review.
•    Accepted Version: The article version that has been formally accepted after peer review, prior to any typesetting for the journal. This is the version accepted by the editor, before proofs, corrections, and typesetting. Also known as the “raw” accepted version of a manuscript.
•    Article of Record: This article version is the “version of record” that has been formally copyedited, typeset, and published online epub ahead of print and/or in a journal issue. It is the same version published in the “Online Now” section of the journal website.

Self-Archiving Policy

Mary Ann Liebert, Inc., publishers offers authors many options and opportunities to self-archive their work. Self-archiving of work is also referred to, or known as, publishing “Green Open Access”.

Authors can self-archive the original submission version of their article on any website or repository without embargo.

Additionally, authors can self-archive the accepted version of their article on their personal websites or institutional repositories only, without embargo. Any archiving of the accepted version for inclusion in subject-based repositories, such as PubMed Central (PMC), should follow the requirements of the funder of the work.  

Authors are not allowed to publish or self-archive the article of record on any website, social media platform, or repository without permission from Mary Ann Liebert, Inc., publishers, unless they publish their paper Gold Open Access (OA). Learn more about publishing your work Open Access here.

Mary Ann Liebert, Inc., publishers’ society partners or associated affiliates may set self-archiving policies independently, outside of the below -mentioned general policies. Authors should refer to the copyright policy of their chosen journal, which can be found on the Journal Collection Page or by contacting the specific journal editorial office directly. In addition, specific funding organizations have separate agreements and authors should refer to the policies of those specific funding agencies prior to the submission of their manuscript.

Original Submission Version

The original submission version of an article is the author's version that has not been peer reviewed.

This version may be placed on:

•    The author's personal website
•    The author's company or institutional repository or archive
•    Any not-for-profit subject-based preprint servers or repositories

Self-archiving of the original submission version is not subject to an embargo period.

If your submission is formally accepted after peer review in one of our journals, authors must include an acknowledgement of acceptance for publication on all archive sites and, following online publication, authors must include the following notice on the first page:

This is the original submission version (pre-peer review) of the following article: [full citation], which has now been formally published in final form at Androgens at [link to final article using the DOI]. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

The original submission version posted may never be updated or replaced with the article of record version unless the author chooses to publish their paper OA under any of the Creative Commons Licenses available through the publisher. If you are interested in publishing your work OA, please feel free to review our Open Access policies and Licenses or contact us.

Accepted Version

Authors may only archive the accepted version of their manuscript on their personal and professional websites, and/or the author’s institutional repository or archive. Any archiving of the accepted version for inclusion in subject-based repositories, such as PubMed Central (PMC), should follow the requirements of the funder of the work. This process may impose additional embargo periods.  

The accepted version may be placed on:
•    The author's personal website
•    The author's company/institutional repository or archive

The accepted version posted must include the following notice on the first page:

This is the accepted version of the following article: [full citation], which has now been formally published in final form at Androgens at [link to final article using the DOI]. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

The posted accepted version may never be updated or replaced with the article of record version unless the author chooses to publish their paper Open Access under any of the Creative Commons Licenses available through the publisher. If you are interested in publishing your work OA, please feel free to review our Open Access policies and Licenses or contact us.

Article of Record

The article of record version may never be archived on a website, or in a repository or research network, unless published Gold Open Access under any of the Creative Commons Licenses available through the publisher. If you have questions, please contact us for more information. You can also review our Open Access policies and Licenses.

Funder Requirements

Mary Ann Liebert, Inc. publishers adheres to national and international funder requirements. Various funders, such as the National Institutes of Health (NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI), The Bill & Melinda Gates Foundation, and UK Research and Innovation (UKRI), for example, have specific requirements for depositing the accepted version and/or the article of record version of the author manuscript in a repository after an embargo period. Authors funded by these organizations should follow the self-archiving terms and conditions of these separate agreements based on the policies of the specific funding institutions. If you have questions, please contact us for more information.

Terms and Conditions for Use of All Self-Archived Article Versions

Authors may use either the original submission version or accepted version in the following ways:

•    For purposes of your own curriculum or teaching, dissertation, thesis, or book provided that all posted versions include the aforementioned notices, and follow all guidelines and requirements specified.
•    To share with researchers and research colleagues provided that such sharing is not for commercial purposes.

The self-archived submitted and accepted versions may only be used in non-commercial capacities. Individual users may view, print, download, and copy self-archived articles, as well as text and data mine the content conditions for non-commercial and non-promotional research and private study purposes, under the following requirements:

•    The authors' moral rights are not compromised and there is clear "attribution" of the author(s) in the shared work.
•    The authors’ integrity remains intact; the work should never be altered in such a way that the author's reputation or integrity may be damaged.
•    Any reuse complies with the copyright policies of the owner of that content.
•    Self-archived content may never be republished verbatim in whole or in part in print or online formats.

 

 

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Your article will be easily searchable on Google, Google Scholar, and other search engines.

 

The Office of Foreign Assets Control (OFAC) of the US Department of the Treasury administers and enforces economic and trade sanctions based on US foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. (Source: https://www.treasury.gov/about/organizational-structure/offices/pages/office-of-foreign-assets-control.aspx)

Our journal editors welcome contributions from researchers around the world; however, they are also required to follow sanction laws and regulations. Upon the date of this update (August 2020), sanction measures imposed by the United States, United Nations, European Union, and Australia are currently in place against the following countries: Cuba, Crimea, Iran, North Korea, and Syria. Journal editors will treat with caution any submission from a sanctioned country regarding the subject matter and will seek appropriate legal advice from the publisher if necessary.

Papers from sanctioned countries that are submitted to any Mary Ann Liebert, Inc., journal MUST contain a confirmation statement after the conclusion section of the manuscript which indicates that EACH listed author confirms that their research is supported by an institution that is primarily involved in education or research.

For further questions, please contact our Director of Production and Editorial Operations.

Androgens: Clinical Research and Therapeutics is published by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801;  Tel:  914-740-2100; Email:  Info@liebertpub.com;  Website:  www.liebertpub.com/andro

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Society Affiliations

The Official Journal of: